DEF: Maison Solutions Inc. Seeks Stockholder Approval for Share Increase, Stock Issuance, and Charter Amendments at 2025 Annual Meeting
Proxy Statement
Maison Solutions Inc. is asking stockholders to vote on proposals including increasing authorized shares, approving a stock issuance related to a recent financing agreement, and amending the company charter to allow stockholder action by written consent at the upcoming annual meeting.
Summary
- Maison Solutions Inc. is holding its 2025 Annual Meeting of Stockholders on April 29, 2025, to vote on several key proposals.
- The proposals include the election of five directors, an increase in the number of authorized Class A Common Stock shares from 92,000,000 to 150,000,000, and approval of a recent stock issuance.
- Stockholders will also vote on an amendment to the company's charter to permit stockholder action by written consent and the ratification of Kreit & Chiu CPA LLP as the company's independent auditor for the fiscal year ending April 30, 2026.
- The Board of Directors recommends voting FOR all director nominees and all listed proposals.
Sentiment
Score: 6
Explanation: The document is primarily informational, outlining proposals for stockholder vote. The sentiment is neutral, with a slight positive leaning due to the potential benefits of the proposed actions, balanced by the risks associated with dilution and financing terms.
Positives
- Increasing authorized shares provides flexibility for future corporate actions, including equity incentives, capital raising, and acquisitions.
- Allowing stockholder action by written consent could reduce costs associated with special meetings.
- The SPA provides the company with immediate financing of $2,745,000 through the issuance of the Initial Note.
- The company has the option to redeem the Initial Note prior to maturity.
Negatives
- The issuance of additional shares will dilute existing stockholders' ownership.
- The conversion price of the Notes can be adjusted, potentially leading to a significant increase in the number of shares issued.
- The SPA includes restrictions on the company's ability to issue other securities without the investor's consent.
- Failure to obtain stockholder approval for the stock issuance could limit the number of shares issuable under the Notes, potentially requiring cash payments instead.
Risks
- The market price of the company's Class A Common Stock could be adversely affected by the issuance of new shares.
- The availability of additional authorized shares may discourage takeover attempts.
- Failure to obtain stockholder approval for the share increase and stock issuance proposals could require the company to seek alternative financing on less favorable terms.
- The company's ability to meet its ongoing business needs and growth strategy depends on its ability to raise capital and satisfy its obligations under the SPA.
Future Outlook
The company intends to use the additional authorized shares for various corporate purposes, including equity incentive plans, capital raising, acquisitions, and strategic relationships. The company's ability to successfully implement its business plans and growth strategy and ultimately maximize value for its stockholders is dependent upon its ability to raise capital and satisfy its ongoing business needs and growth strategy.
Management Comments
- The Board of Directors recommends that you vote FOR the election of all the director nominees; FOR the approval of an amendment to the Company's Amended and Restated Articles of Incorporation to increase the number of authorized shares of Class A Common Stock; FOR the approval, for purposes of complying with Nasdaq Listing Rule 5635(d), of the full issuance of shares of Class A Common Stock issuable by the Company pursuant to the Notes and Warrant; FOR the approval of an amendment to the Company's Charter to permit stockholders of the Company to take action by written consent; and FOR the ratification of the selection of Kreit & Chiu CPA LLP as the Company's independent certified public accountants for the fiscal year ending April 30, 2026.
Industry Context
Many companies seek to increase their authorized share capital to provide flexibility for future financing and strategic opportunities. The use of convertible notes is a common financing tool, particularly for smaller companies. The proposed changes to corporate governance reflect a trend towards greater stockholder empowerment.
Comparison to Industry Standards
- Increasing authorized share capital is a common practice among publicly traded companies to provide flexibility for future corporate actions.
- Convertible notes are frequently used by companies seeking capital, especially smaller companies or those with limited access to traditional financing.
- The specific terms of the SPA, including the conversion price and floor price, would need to be compared to similar financing agreements to assess their favorability.
- The proposed amendment to allow stockholder action by written consent aligns with trends towards greater stockholder rights, although it is not universally adopted.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Operating Officer | Tao Han | Xi (Jacob) Cao | February 21, 2025 | Tao Han's resignation |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Amendment to Charter | Increase the number of authorized shares of Class A Common Stock from 92,000,000 shares to 150,000,000 shares. | Upon filing with the Secretary of State of Delaware | Provides flexibility for future corporate actions, but dilutes existing stockholders' ownership. |
| Amendment to Charter | Permit stockholders of the Company to take action by written consent. | Upon filing with the Secretary of State of Delaware | Reduces costs associated with special meetings, but requires Board approval. |
Related Party Transactions
- The company has engaged in several related party transactions, including acquisitions, payables to related parties, and sales and purchases of supermarket products with entities controlled by John Xu and his spouse, Grace Xu.
- These transactions are subject to review and approval by the Audit Committee.
Stakeholder Impact
- Stockholders will be impacted by the potential dilution from the issuance of new shares.
- The company's employees and customers may benefit from the increased financial flexibility provided by the financing.
- The company's creditors may be affected by the terms of the SPA and the issuance of the Notes.
Next Steps
- Stockholders need to review the proxy statement and vote on the proposals.
- The company will hold its Annual Meeting on April 29, 2025, to count the votes and implement the approved proposals.
- If the proposals are approved, the company will file the necessary amendments to its charter with the Secretary of State of Delaware.
- The company will proceed with the stock issuance under the terms of the SPA, subject to stockholder approval and Nasdaq rules.
Key Dates
| Date | Description |
|---|---|
| March 28, 2025 | Record date for the Annual Meeting |
| April 3, 2025 | Board adopted resolutions approving the Charter Amendment |
| April 14, 2025 | Proxy statement and form of proxy first being mailed to stockholders |
| April 28, 2025 | Deadline to vote through the Internet |
| April 29, 2025 | Date of the 2025 Annual Meeting of Stockholders |
| April 30, 2026 | Fiscal year ending date for auditor ratification proposal |
| December 15, 2025 | Deadline for stockholders to submit proposals for inclusion in the 2026 Proxy Statement |
| December 30, 2025 | Earliest date for stockholders to submit a proposal or nomination for the 2026 Annual Meeting |
| January 29, 2026 | Latest date for stockholders to submit a proposal or nomination for the 2026 Annual Meeting |
Keywords
proxy statement, annual meeting, stockholder vote, authorized shares, stock issuance, convertible note, charter amendment, corporate governance, director election, auditor ratification
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.